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Introduction: Increased levels of angiotensin II (Ang II) and activity of Ang II receptor type 1 (AT1R) elicit detrimental
effects in cardiovascular disease. However, the role of Ang II receptor type 2 (AT2R) remains poorly defined.
Mesenchymal stem cells (MSCs) replenish and repair endothelial cells in the cardiovascular system. Herein, we
investigated a novel role of angiotensin signaling in enhancing vascular endothelial growth factor (VEGF)-A-mediated
differentiation of MSCs into endothelial cells (ECs).
Methods: Bone marrow was aspirated from the femurs of Yucatan microswine. MSCs were extracted via ficoll density
centrifugation technique and were strongly immunopositive for MSC markers, CD44, CD90, and CD105, but negative
for hematopoietic markers, CD14 and CD45. Subsequently, naïve MSCs were differentiated for 10 days in varying
concentrations and combinations of VEGF-A, Ang II, and AT1R or AT2R antagonists. Markers specific to ECs were
determined by FACS analysis.
Results: AT1R and AT2R expression and cellular localization was demonstrated in MSCs stimulated with VEGF-A and
Ang II via quantitative RT-PCR and immunofluorescence, respectively. Differentiation of naïve MSCs in media containing
Ang II (2 ng/ml) plus low-dose VEGF-A (2 ng/ml) produced a significantly higher percentage of cells that were positive
for expression of EC markers (for example, platelet endothelial cell adhesion molecule, vascular endothelial Cadherin
and von Willebrand factor) compared to VEGF-A alone. Ang II alone failed to induce EC marker expression. MSCs
differentiated with the combination of Ang II and VEGF-A were capable of forming capillary tubes using an in vitro
angiogenesis assay. Induction of EC marker expression was greatly attenuated by co-treatment of Ang II/VEGF-A with
the AT2R antagonist PD123319, but not the AT1R antagonist telmisartan.
Conclusions: We report the presence of functional AT2R receptor on porcine bone marrow-derived MSCs, where it
positively regulates EC differentiation. These findings have significant implications toward therapeutic approaches
based on activation of AT2R, which could be a means to stimulate regeneration of damaged endothelium and prevent
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Occlusive cardiovascular diseases are the foremost cause
of mortality in the United States, totaling more than
33% of deaths per year with 2,200 fatalities per day [1,2].
Development of atherosclerotic plaque and intimal
thickening in carotid and coronary arteries are dominant
predictors of future myocardial infarction [3]. Following
myocardial infarction and/or ischemia, interventional
procedures, including angioplasty and stenting, are per-
formed. Endothelial dysfunction remains an inherent
secondary effect of these procedures [4]. Deployment of
drug-eluting stents in coronary arteries causes endothe-
lial cell wasting, which contributes to neointimal hyper-
plasia of the underlying smooth muscle cells, restenosis
of the artery and even in-stent thrombosis. Following
angioplasty and stent replacement, reocclusion rates are
as high as 20% of total procedures performed per year [5].
The high incidence of complications due to restenosis is a
large burden on healthcare cost. Even worse, acute coron-
ary thrombosis is a cause of sudden fatalities [6].
Cell-based therapies have been explored as treatments
for heart disease [7]. In particular, mesenchymal stem cell
(MSC)-based treatments have been proposed as a poten-
tial method for regenerating and/or rejuvenating dys-
functional endothelium [8]. MSCs are multipotent cells
capable of differentiating into cells of mesodermal
lineage [9]. Vascular endothelial growth factor (VEGF-
A) is the best-defined growth factor that promotes dif-
ferentiation of MSCs into endothelial cells (ECs) [10].
VEGF-A is an EC mitogen that plays an essential role
in both vasculogenesis and angiogenesis. VEGF-A inter-
action with its cognate tyrosine kinases induces multiple
pro-angiogenic pathways that promote cell survival, mi-
gration, and proliferation [11,12]. Indeed, stimulation of
VEGF receptor 2 on bone marrow-derived mesenchymal
stem cells (BM-MSCs) by treatment with recombinant
VEGF-A is an efficient way to induce differentiation of
cultured MSCs into ECs in vitro [13].
To utilize MSCs in endothelial regeneration in vivo, it is
critical to identify molecular agonists that can regulate the
differentiation of MSCs into EC-like cells [14,15]. The
angiotensin II (Ang II) receptors AT1R and AT2R are
G protein-coupled receptors (GPCRs) of great importance
to cardiovascular function. The precursor angiotensinogen
is cleaved by renin to produce angiotensin I, which is fur-
ther cleaved to Ang II by angiotensin-converting enzyme
[16]. Ang II binds and activates AT1R and AT2R, which
are both expressed in important cardiovascular tissues, in-
cluding vascular smooth muscle cells and ECs [17].
Through AT1R and AT2R, Ang II has divergent effects
that are critical for vascular homeostasis. Ang II stimu-
lates vascular smooth muscle contraction of the coronary
blood vessels [18]. At the same time, Ang II can induce
endothelium-dependent production of the vasodilatornitric oxide [19-21]. AT1R and AT2R could therefore
play an important role in the differentiation of MSCs
into ECs. In this study, we show expression of ATR1
and ATR2 on porcine bone BM-MSCs. We demonstrate
that activation of AT2R elicits a synergistic response with
VEGF-A to augment the differentiation of BM-MSCs to
ECs. These findings have significant clinical implications
with regard to the effects of medications that inhibit Ang
II production or activation of AT2R on endothelial func-
tion or regeneration. Optimization of protocols for EC dif-
ferentiation will be vital for cell-based therapies aimed at
repairing damaged endothelium.
Materials and methods
Mesenchymal stem cell isolation and differentiation
MSCs were isolated, characterized, and differentiated
from Yucatan microswine femurs as reported previously
by our group [22]. All animal procedures were in com-
pliance with applicable federal, state, and local laws and
regulations, and institutional policies. The Institutional
Animal Care and Use Committee of Creighton Univer-
sity approved the animal research protocol. Cells used
for experiments in this study were between passages 3
and 5. The isolated MSCs were CD14–CD45–CD44+
CD90+CD105+. The growth media used to harvest and
culture MSCs was Dulbecco’s modified Eagle’s medium
with 10% fetal bovine serum. The differentiation media
(DM) used for differentiation was endothelial growth me-
dia 2 (EGM-2) containing 2 ng/ml, 25 ng/ml, or 50 ng/ml
recombinant human VEGF-A165 (Peprotech, Rocky Hill,
NJ, USA), and/or 2 ng/ml, 25 ng/ml, or 50 ng/ml recom-
binant human Ang II (Sigma; St. Louis, MO, USA). Basic
EGM-2 was used as negative control DM. Stimulation
began when MSCs were at 50% confluency and continued
for 10 days. The cell cultures were maintained at 37°C in a
humidified atmosphere containing 5% carbon dioxide.
Media containing varying concentrations of VEGF-A, Ang
II, and ATR inhibitor were changed every 48 hours.
Fluorescence-activated cell sorting characterization of
naïve MSCs and ECs
Briefly, cells (1 × 106/ml) were washed with phosphate-
buffered saline (PBS) containing 4% fetal bovine serum
and incubated with primary antibodies conjugated to
fluorophore (fluorescein isothiocyanate for 30 minutes at
4°C in the dark. The antibody concentrations followed
the specifications of the manufacturer. The cells were
further washed three times in PBS and resuspended in
750 μl FACS-FIX. Flow cytometry was performed on a
BD FACSAria I/II System (BD Biosciences, San Jose,
CA, USA). Naïve MSCs highly expressed stem cell
markers CD44, CD90 and CD105. The cells from the same
gate were negative for the macrophage marker CD14
and the hematopoietic stem cell marker CD45. After
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platelet endothelial cell adhesion molecule-1 (PECAM)–
fluorescein isothiocyanate (ebiosciences, San Diego, CA,
USA), vascular endothelial cadherin (VE-cadherin)–fluor-
escein isothiocyanate (ebiosciences), and von Willebrand
factor (vWF)–fluorescein isothiocyanate (ebiosciences).
Transfection
For small interfering RNA (siRNA)-mediated knockdown
experiments, MSCs were transfected using the Amaxa
Nucleofector II Device with the MSC Nucleofector Kit
(Lonza, Basel, Switzerland) according to the manufac-
turer’s optimized protocol for MSCs. For each nucleofec-
tion sample, we harvested 2.5 × 105 cells (cell counter;
Beckman Coulter, Brea, CA; USA). Briefly, MSCs were
washed in Dulbecco’s modified Eagle’s medium supple-
mented with 200 U/ml penicillin G sulfate plus 200 mg/ml
streptomycin sulfate. Nucleofector medium (100 μl) con-
taining siRNA (5 to 50 nM; Origene, Rockville, MD, USA)
was administered in a single square wave pulse in a
4 mm diameter cuvette. After electroporation, MSCs
were washed with PBS three times, then transferred
into DM or growth media and incubated at 37°C. For
transfection control, an equivalent amount of scram-
bled siRNA was used in either DM. At 72 hours post
transfection, cell cultures were harvested and protein
lysates were isolated for western blot analysis.
Western blot
Protein fractions were isolated using the active motif kit
(Active Motif, Carlsbad, CA, USA). Total protein lysates
were quantified by Bradford assay. Proteins were sepa-
rated by 10% SDS-PAGE, transferred onto a nitrocel-
lulose membrane, and blocked overnight in blocking
solution (1× TBS, pH 7.6, 0.1% Tween-20, and 5% w/v
nonfat dry milk). The membrane was then incubated
with antibodies specific for VEGF-A (Ab105846, 1:500;
Abcam; Cambridge, MA, USA). As a loading control, the
membrane was probed for glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) (1:1,000, NB300-221; NOVUS
Biological; Littleton, CO, USA). The membrane was then
incubated with horseradish peroxidase-conjugated sec-
ondary antibody (1:1,000) in blocking solution for 1 hour
at room temperature. Horseradish peroxidase activity was
detected by incubating the membrane in chemilumines-
cence solution (Bio-Rad, Hercules, CA, USA). The expos-
ure time was adjusted to keep the integrated optical
densities within a linear and nonsaturated range. Densito-
metric analysis was carried out using a UVP Bioimaging
system (UVP, Minneapolis, MN, USA).
Quantitative RT-PCR
Total RNA was isolated from naïve MSCs using Trizol re-
agent (Sigma) according to the manufacturer’s instructions.The yield of RNA was quantified using a Nanodrop
(Thermo-Scientific, Rockford, IL, USA). First-strand
cDNA synthesis was performed following the manufac-
turer’s instructions (Improm II reverse transcription kit;
Promega, Madison, WI, USA) using oligo dT primers.
Real-time quantitative PCR was performed using SYBR
Green Master Mix and a Real-time PCR system (CFX96;
BioRad Laboratories, Hercules, CA, USA). The following




and AT2R-R, 5′-CATCTTCAGGACTTGGTCAC-3′; and
GAPDH-F, 5′-CCCATCACCATCTTCCAGGAG-3′ and
GAPDH-R, 5′-GTTGTCATGGATGACCTTGGCC-3′.
Primers were obtained from Integrated DNA Technolo-
gies (Coralville, IA, USA). The specificity of the primers
was confirmed by running a melting curve (data not
shown). The thermocycler conditions were as follows:
5 minutes at 95°C for initial denaturation, and 40 cycles of
30 seconds at 95°C, 30 seconds at 55 to 60°C (depending
upon the primer annealing temperatures), and 30 seconds
at 72°C. Fold expression of mRNA transcripts relative to
controls was determined after normalizing to GAPDH.
Angiotensin receptor blockade
To analyze the effects of AT1R and AT2R on differenti-
ation, MSCs were pre-incubated with 5 μM Telmisartan
(an AT1R blocker) or 5 μM PD123319 (an AT2R bloc-
ker) for 1 hour. Pretreated MSCs were then cultured in
DM containing 1 μM of either ATR blocker. In prelim-
inary experiments, titration was performed for AT1R-
specific and AT2R-specific antagonists (1 to 20 μM) for
24 hours to determine the optimal concentration that
had no effect on cell viability or proliferation. Cells were
then detached by with 0.25% trypsin/ethylenediamine
tetraacetic acid, counted, and evaluated by annexin V/PI
assay. Florescence-activated cell sorting analysis revealed
that >95% of cell were viable at concentrations of ATR
blockers between 1 μM and 5 μM. MSCs were then in-
duced to undergo differentiation with differentiating
media containing the indicated concentrations of VEGF-A
alone or in combination with Ang II and/or ATR
antagonists.
Immunofluorescence
Cells were incubated in blocking solution containing
PBS, 0.25% Triton X-100, 10 mg/ml bovine serum albu-
min, and 5% normal goat serum (Jackson Laboratories,
West Grove, PA, USA) for 1 hour at room temperature.
The cells were incubated with primary antibodies se-
lective for anti-AT1R (Ab9391, 1:1,000; abcam) or anti-
AT2R (Ab19134, 1:1,000; abcam) for 1 hour at room
temperature. After washing with PBS containing 0.1%
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secondary antibody (affinity purified goat anti-rabbit Cy2
and Cy3 antibody, 1:500, Jackson laboratories; West
Grove, USA) was applied to the sections for 1 hour in
the dark to visualize AT1R-labeled and AT2R-labeled
cells (Jackson Immunolabs, West Grove, PA, USA).
Negative controls were run in parallel either using rabbit
pre-immune serum PAC-767 (Pacific Immunology,
Ramona, CA, USA) instead of primary antibody or by
complete omission of primary antibody. Negative control
was absent of staining. Sections were washed with PBS
with 0.1% bovine serum albumin three times for 5 minutes
and dipped into distilled water for 2 seconds. Fluorescence
was preserved by sealing specimens with a solution of
equal parts of PBS and glycerol containing 10 mg/ml
n-propyl gallate, and 1.5 mg/ml 4′,6-diamidino-2-phe-
nylindole. To prevent the escape of the mounting medium
from the cover slips, a single layer of nail polish was
placed around the edges. Pictures were taken within 1 hour
of mounting using an Olympus DP71 camera (Olympus,
St Louis, MO, USA).
Angiogenesis assay
After stimulation for 10 days, MSCs were harvested and
an angiogenesis assay was performed according to the
manufacturer’s protocol (Chemicon, Temecula, CA,
USA). Polymerized EC matrices were prepared by incu-
bating 100 μl ECMatrix gel solution into each well of a
24-well plate at 37°C for 1 hour. The stimulated cells
were seeded at a concentration of 1 × 104 cells on EC
matrices. EGM-2 medium (300 μl) was added to each
well and maintained at 37°C and 5% carbon dioxide in-
cubation for 6 hours. The formation of capillary tubes
was analyzed using an inverted phase contrast micro-
scope (CKK41; Olympus).
Statistical analysis
Data are presented as the mean ± standard deviation from
three to six independent experiments. For eachFigure 1 Characterization of bone marrow-derived mesenchymal stem
(MSCs) at passages 3 to 5 stained negatively for CD14 (monocyte marker
that are indicative of MSC lineage, including CD44 (hyaluronic acid recep
stem-like properties.experiment, MSC cultures were isolated from the femoral
bone of separate pigs. Data were analyzed using GraphPad
Prism, GraphPad Software; La Jolla, California, USA. Mul-
tiple group comparisons were performed by Bonferroni’s
multiple comparison tests using one-way analysis of vari-
ance. P <0.05 was accepted as statistically significant.
Results
Characterization of bone marrow-derived MSCs
Primary cultures of MSCs isolated from porcine bone mar-
row exhibited fibroblastoid morphology typical of MSCs
[24]. Flow cytometry data revealed that cells at passages 3
to 5 stained negatively for CD14 (monocyte marker) and
CD45 (hematopoietic marker) (Figure 1). The same MSCs
expressed CD44 (hyaluronic acid receptor), CD90 (Thy-1),
and CD105 (Endoglin), characteristic of MSCs (Figure 1).
Expression of AT1R and AT2R on naïve MSCs
Control porcine BM-MSCs were cultured in basic EGM-
2 control media containing 10% fetal bovine serum.
Additional MSC cultures were stimulated with VEGF-A
(2 ng/ml) alone, Ang II (2 ng/ml) alone, or the combin-
ation of VEGF-A/Ang II for 24 hours. Quantitative RT-
PCR was used to analyze the mRNA expression of AT1R
and AT2R on treated MSCs. The data reveal that the
combination of VEGF-A and Ang II produced a greater
induction in the mRNA expression of both AT1R and
AT2R on differentiating MSCs than VEGF-A or Ang II
alone (Figure 2A). Human umbilical vein endothelial
cells (HUVECs) were used as an independent positive
control for ECs. HUVEC AT1R and AT2R mRNA ex-
pression was significantly greater than that of treated or
naïve MSCs (Figure 2A). Likewise, AT1R and AT2R ex-
pression on MSCs was confirmed by immunofluores-
cence using antibodies that have been validated for
specificity [25,26] (Figure 2B). AT1Rs and AT2Rs were
expressed heterogeneously in the BM-MSC population
and, in many cases, were co-expressed on the same cell
(Figure 2B).cells. Flow cytometry data revealed that mesenchymal stem cells
) and CD45 (hematopoietic marker), but expressed surface markers
tor), CD90 (Thy-1), and CD105 (Endoglin). Isolated MSCs exhibited
Figure 2 Effect of VEGF-A and angiotensin II treatment on the expression of angiotensin receptors. Bone marrow-derived mesenchymal
stem cells (BM-MSCs) were cultured in vascular endothelial growth factor (VEGF-A; 2 ng/ml), angiotensin II (Ang II; 2 ng/ml), or combined VEGF-A/
Ang II for 24 hours. Expression of angiotensin receptor AT1R and AT2R mRNA was analyzed via quantitative RT-PCR, and human umbilical vein
endothelial cells (HUVECs) were used as positive control (A). Immunostaining demonstrating co-localization of AT1R and AT2R on the cell
membrane of BM-MSCs treated with VEGF-A (2 ng/ml) plus Ang II (2 ng/ml). AT1R stained in red co-localized with AT2R labeled in green to
produce a yellow merge (B). One image representative of three independent experiments is shown. Data are representative of three independent
experiments performed from three different cultures from swine bone marrow. *P <0.05 vs. naïve MSCs. #P <0.05 vs. Ang II-treated MSCs, n = 3.
DAPI, 4′,6-diamidino-2-phenylindole.
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endothelial cell markers on MSCs
Our group previously reported that 50 ng/ml VEGF-A
(high-dose VEGF-A) induces the expression of EC mar-
kers PECAM, vWF, and VE-cadherin [22]. Here, we de-
monstrate that dose-dependent treatment of BM-MSCs
with 2 ng/ml, 25 ng/ml, and 50 ng/ml VEGF-A induces
a coordinated increase in immunopositive expression of
the EC markers PECAM-1, VE-cadherin, and vWF. Spe-
cifically, low-dose VEGF-A (2 ng/ml) resulted in a small
increase in the percentage for vWF+ cells (16 ± 2%),
PECAM-1+ cells (13 ± 4%) and VE-cadherin+ cells (11 ±
7%) (Figure 3A,I). An intermediate dose of VEGF-A
(25 ng/ml) produced a higher positive percentage of
vWF+ cells (39 ± 2%), PECAM-1+ cells (33 ± 2%), and
VE-cadherin+ cells (43 ± 5) (Figure 3B,I). Finally, high-
dose VEGF-A (50 ng/ml) produced the highest percent-
age of vWF+ cells (78 ± 1%), PECAM-1+ cells (61 ± 1%),
and VE-cadherin+ cells (65 ± 1%) (Figure 3C,I). Differ-
entiation media supplemented only with Ang II (2 to
50 ng/ml) had no significant effect on the expression
of vWF, PECAM-1, and VE-cadherin (Figures 3D,E,F,I).
HUVECs were used as a positive control for EC marker
expression. HUVECs were highly immunopositive forPECAM-1, VE-cadherin, and vWF (>90% immunoposi-
tivity) (Figure 3G,I), whereas naïve BM-MSCs were ne-
gative for EC markers (Figure 3H,I).
Synergistic effect of VEGF-A and angiotensin II
Low-dose VEGF-A (2 ng/ml) alone or Ang II alone (2,
25, or 50 ng/ml) failed to induce appreciable expression
of EC markers (Figure 3I). However, co-treatment of
naïve BM-MSCs with low-dose VEGF-A (2 ng/ml) in
combination with Ang II caused a marked increase in
the percentage of immunopositive cell expression for
the EC markers tested (Figure 4A,B,C,D). Specifically,
low-dose VEGF-A (2 ng/ml) and Ang II (2 ng/ml) en-
hanced immunopositive cell levels to 65 ± 2% vWF+ cells,
60 ± 2% PECAM-1+ cells, and 61 ± 1% VE-cadherin+ cells
(Figure 4A,D). Increasing the concentration of Ang II to
25 or 50 ng/ml together with 2 ng/ml VEGF-A demon-
strated no further significant increase in the percentage
cells positive for the EC markers (Figure 4B,C,D).
Differentiated MSCs form cobblestone morphology and
capillary tubes
Classically, naïve MSCs display a fibroblastic morphology
[22], whereas ECs display cobblestone morphology [22].
Figure 3 Immunopositivity of endothelial cells differentiated from mesenchymal stem cells in the presence of VEGF-A for PECAM, vWF,
and VE-cadherin. Representative grids for von Willebrand factor (vWF) are shown. Low-dose vascular endothelial growth factor (VEGF-A) induced
a small increase in immunopositivity for platelet endothelial cell adhesion molecule-1 (PECAM-1), vWF, and vascular endothelial cadherin
(VE-cadherin) (A, I). Higher concentrations of VEGF-A (25 to 50 ng/ml) induced a marked increase in expression of endothelial cell (EC) markers
(B, C, I). Angiotensin II (Ang II; 2 to 50 ng/ml) had no effect on the expression of EC markers (D, E, F, I). Human umbilical vein endothelial cells
(HUVECs) were used as an independent positive control showing ≈ 99% immunopositivity to vWF (G, I). Naïve MSCs were negative for EC marker
expression (H, I). Graphical representation of the fluorescence-activated cell sorting (FACS) data (I). Note that HUVECs were excluded from the
statistical analyses. *P <0.05 vs. naïve MSCs. #P <0.05 vs. VEGF-A (2 ng/ml). αP <0.05 VEGF-A (50 ng/ml) vs. VEGF-A (25 ng/ml)-treated MSCs, n = 3.
MSC, mesenchymal stem cell.
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a fibroblastoid shape (Figure 5A). High-dose VEGF-A
(50 ng/ml) induced the cobblestone shapes (Figure 5B);
however, low-dose VEGF-A (2 ng/ml) produced much
less of an effect (Figure 5C). Combined treatment with
low-dose VEGF-A (2 ng/ml) and Ang II (2 ng/ml) resulted
in nests of cobblestone-shaped cells (Figure 5D). Ang II
(2 ng/ml) alone had no effect (Figure 5E). HUVECs dem-
onstrated rigid cobblestone interconnections (Figure 5F).
Next, we examined the higher order formation of ca-
pillary tube structures typical of endothelium matur-
ation. After 10 days of stimulation, cells were seeded onto
ECMatrix gel to assess angiogenesis. Naïve MSCs cul-
tured in basic EGM-2 control media and incubated on
ECMatrix gel did not form capillary structures (Figure 5G).
MSCs differentiated in high-dose VEGF-A were capable offorming characteristic capillary structures (Figure 5H),
similar to the positive control HUVECs (Figure 5L).
In contrast, MSCs differentiated in low-dose VEGF-A
(2 ng/ml) showed weak signs of capillary tube formation
(Figure 5I). Combined treatment with low-dose VEGF-A
(2 ng/ml) and Ang II (2 ng/ml) resulted in complex mesh-
like formation in addition to closed polygonal structures
(Figure 5J). Ang II (2 ng/ml) alone had no effect on capil-
lary formation (Figure 5K).
AT2R antagonist inhibits angiotensin II-stimulated
endothelial cell differentiation
Ang II is capable of transducing its effects via AT1R and
AT2R. In order to determine whether AT1R or AT2R is
pivotal to Ang II-mediated induction of EC marker ex-
pression, we utilized selective receptor antagonists. Naïve
Figure 4 Synergistic effect of angiotensin II and low-dose VEGF-A to promote mesenchymal stem cell differentiation into endothelial
cells. Co-culture of naïve bone marrow-derived mesenchymal stem cells (BM-MSC) with vascular endothelial growth factor (VEGF-A; 2 ng/ml)
and angiotensin II (Ang II; 2 ng/ml) resulted in significantly increased expression of platelet endothelial cell adhesion molecule-1 (PECAM-1), von
Willebrand factor (vWF), and vascular endothelial cadherin (VE-cadherin) (A). Increasing the dose of Ang II in combination with the low dose of
VEGF-A did not result in further increase in EC marker expression (B, C, D). Note that human umbilical vein endothelial cells were excluded from
the statistical analyses. *P <0.05 vs. naïve MSCs. #P <0.05 vs. VEGF-A (2 ng/ml)-treated MSCs, n = 3.
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1 hour. Subsequently, the naïve MSCs were cultured in
differentiation media containing VEGF-A (2 ng/ml) and
Ang II (2 ng/ml) plus either 1 μM telmisartan or 1 μM
PD123319 for 10 days. Our results showed that telmisartan
(10-6 M) slightly diminished immunopositive expression of
EC markers with 59 ± 2% vWF+ cells, 58 ± 1% PECAM-1+
cells, and 57 ± 6% VE-cadherin+ cells (Figures 6A,C).
Conversely, PD123319 (10–6 M) significantly attenuated
the induction of EC immunopositive phenotype by Ang II/
VEGF-A to a level of 27 ± 1% vWF+ cells, 31 ± 3% PECAM-
1+ cells, and 28 ± 2% VE-cadherin+ cells (Figure 6B,C).
These data strongly support the critical role of AT2Rs
in the synergistic effect of Ang II with VEGF-A in MSC
differentiation into ECs.
Angiotensin II-induced VEGF secretion does not account
for MSC differentiation into endothelial cells
Previous studies have demonstrated that Ang II stimu-
lates the synthesis of VEGF in rat BM-MSCs through an
AT1R-dependent mechanism. Thus, we tested VEGF-A
mRNA expression in MSC cultures stimulated with Ang
II (2 ng/ml) alone, VEGF-A (2 ng/ml) alone, or the com-
bination of VEGF-A/Ang II for 24 hours. Treatment
with either Ang II or VEGF-A significantly upregulated
VEGF-A mRNA compared with naïve MSCs (Figure 7A).
Furthermore, the combination of VEGF-A and Ang IIproduced an even greater induction VEGF-A mRNA
(Figure 7A).
To address the role of endogenous VEGF-A in MSC
differentiation, experiments using siRNA directed to
VEGF-A were performed. siRNA-mediated knockdown
of endogenous VEGF-A was confirmed by western blot
of protein lysates from MSCs stimulated with VEGF-A
(2 ng/ml) plus Ang II (2 ng/ml) (Figure 7B). Knockdown
of endogenous VEGF-A failed to prevent induction of
EC marker expression during differentiation with the
combination treatment of exogenous VEGF-A plus Ang
II (Figure 7C,D,E).
Discussion
MSCs offer remarkable potential in regenerative medi-
cine and are currently being investigated for the treat-
ment of cardiovascular disease [27,28]. MSCs are present
in various organs, including the bone marrow, adipose
tissue, liver, and spleen [25]. MSCs are characterized as a
plastic adherent population, expressing CD44, CD73,
CD90, and CD105 and lacking CD11b, CD19, CD34, or
HLA-DR surface molecules [29-31]. MSCs can be differ-
entiated into cells of the mesoderm, including osteocytes,
chondrocytes, and adipocytes [29,30]. Strategies for dif-
ferentiating BM-MSCs into ECs have therapeutic poten-
tial in cardiovascular diseases and tissue engineering
[30,31].
Figure 5 Cell morphology of differentiated mesenchymal stem cells into endothelial cells. Images taken by inverted microscope after
10 days of stimulation. Control mesenchymal stem cells (MSCs) cultured in growth media retained fibroblastoid morphology (A). MSCs
differentiated in high-dose vascular endothelial growth factor (VEGF-A) changed into the cobblestone shape typical of endothelial cells (B);
however, low-dose VEGF-A produced less of an effect (C). Combination treatment with low-dose VEGF-A and low-dose angiotensin II (Ang II) also
induced cobblestone morphology (D), but Ang II alone had no effect (E). Positive control (human umbilical vein endothelial cells (HUVECs))
demonstrated rigid cobblestone morphology (F). Capillary formation by differentiated MSCs into endothelial cells (ECs) (G, H, I, J, K, L). After
10 days of stimulation, cells were seeded onto ECMatrix gel. Naïve MSCs cultured in control media and incubated on the matrix did not form
elliptical structure (G). High-dose VEGF-A was capable of forming characteristic capillary structures associated with EC regeneration (H). MSCs
differentiated in low-dose VEGF-A started forming elliptical structures. However, individual cells did not connect with each other (I). Combination
treatment with low dose VEGF-A and Ang II resulted in complex mesh-like formation in addition to closed polygonal structure (J). Ang II alone
did not induce any mesh-like structure or connections (K). The effect of the combined treatment was more striking compared with HUVEC cells
forming capillaries (L). One image representative of three independent experiments performed from three different swine bone marrow samples
is shown.
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capable of stimulating the differentiation of MSCs or
progenitor ECs into ECs [22,32]. However, the mitogenic
effects of VEGF-A make it unsuitable for therapeutic
applications, especially at high doses. The novel finding
of this study is that AT2R mediates the synergistic ef-
fect that the combination of Ang II and VEGF has topromote differentiation of swine BM-MSCs into ECs.
Our data suggest that AT2R could be critical to repair
and/or regeneration of damaged vascular endothelium.
Intriguingly, it has been observed that Ang II levels are
increased during occlusive vascular pathologies where the
endothelium is severely injured and denuded, such as in
balloon angioplasty [33]. At the site of injury, MSC traffic
Figure 6 Effect of antagonists for AT1R and AT2R on immunopositivity for endothelial cell markers. Mesenchymal stem cells (MSCs) were
pretreated with either angiotensin receptor AT1R or AT2R inhibitor and then cultured with angiotensin II (Ang II) and vascular endothelial growth
factor (VEGF-A). PD123319, an AT2R inhibitor, significantly reduced the expression of platelet endothelial cell adhesion molecule-1 (PECAM-1), von
Willebrand factor (vWF) and vascular endothelial cadherin (VE-cadherin) (B), whereas there was a lesser effect of the AT1R inhibitor telmisartan
(A). Bar diagram showing data from six individual experiments (C). Note that human umbilical vein endothelial cells were excluded from the
statistical analyses. *P <0.05 vs. VEGF-A (2 ng/ml) plus Ang II (2 ng/ml)-treated MSCs. #P <0.05 telmisartan vs. PD123319-treated MSCs, n = 3.
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upregulated [31]. An increase in the local production of
Ang II acts to stimulate proliferation of vascular smooth
muscle cells and constriction of vascular muscle via acti-
vation of AT1R. In terms of AT2R, results from this study
suggest that Ang II may also act on AT2R to stimulate re-
pair or regeneration of the damaged endothelium.
A study by Shi and colleagues investigated the effects
of Ang II on rat BM-MSCs [33]. The study found that
treatment with Ang II (100 nM; equivalent to ~105 ng/ml)
induced VEGF production in MSC culture media from ap-
proximately 140 pg/ml to 350 pg/ml [33]. According to
our data using a low-dose of VEGF-A (2 ng/ml), such a
low level alone is not effective in upregulating EC marker
expression or in promoting MSC differentiation into ECs.
Furthermore, we found that siRNA-mediated knockdown
of endogenous VEGF-A did not alter the induction of EC
marker expression mediated by the combination of ex-
ogenous VEGF-A plus Ang II. Thus, although Ang II and
VEGF-A stimulate the endogenous production of VEGF,
this effect has only a minor contribution to MSC differenti-
ation into ECs. As a case in point, treatment of MSCs with
Ang II alone was not sufficient to induce EC marker ex-
pression. It is also important to consider that it is necessary
under the differentiation protocol for the media to bechanged every 48 hours in order to maintain cell viability.
The effects of endogenous production of VEGF and other
factors that accumulate in the conditioned media are nulli-
fied each time the cells are switched to fresh media.
Shi and colleagues also demonstrated that Ang II-
stimulated VEGF production by rat BM-MSCs was inhi-
bited much more by the AT1R antagonist losartan than
the AT2R antagonist PD123319 [33]. Mechanistically,
Ang II-mediated induction of VEGF was shown to occur
through extracellular signal regulated kinase (p42/44,
ERK1/2) and Akt pathways via AT1R. Results from the
current study indicate that AT1R inhibition caused only
a slight reduction in EC marker expression upon co-
treatment with VEGF-A/Ang II. Rather, AT2R plays a
major role since treatment of MSCs with the AT2R an-
tagonist PD123319 (10–6 M) caused a marked attenu-
ation of EC marker induction by differentiation in the
presence of exogenous Ang II/VEGF-A. The specific sig-
nal transduction pathways downstream of AT2R activa-
tion with regard to the MSC versus EC phenotype are
not currently well understood.
ATR-mediated and VEGF receptor-mediated signaling
involves downstream mediators including c-Jun NH2-
terminal kinase, p38 mitogen-activated protein kinase,
[34] ERK1/2 [35], and SHP-1 [35]. In particular, AT2R-
Figure 7 Silencing of endogenous VEGF-A lacks an effect on mesenchymal stem cell differentiation into endothelial cells. Differentiating
mesenchymal stem cells (MSCs) were transfected with small interfering RNA (siRNA) directed against vascular endothelial growth factor (VEGF-A)
and then examined for endothelial cell (EC) marker expression. Treatment of MSCs with the cocktail of VEGF-A (2 ng/ml) plus angiotensin II (Ang
II; 2 ng/ml) for 24 hours induced a synergistic increase in VEGF transcript as compared with VEGF-A alone or Ang II alone (A). VEGF-A mRNA was
normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA (A). Standardization experiments demonstrated that 50 nM siRNA
directed against VEGF completely abrogated VEGF protein expression (B). Fluorescence-activated cell sorting analysis revealed that there was no
significant difference in EC marker expression between differentiating MSCs that received VEGF-A siRNA or scrambled control siRNA (C, D, E).
Note that human umbilical vein endothelial cells (HUVECs) were excluded from the statistical analyses. *P <0.05 vs. naïve MSCs. #P <0.05 vs.
VEGF-A (2 ng/ml)-treated MSCs or Ang II (2 ng/ml)-treated MSCs alone, n = 3.
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tric oxide [36,37]. Interestingly, nitric oxide is reported
to augment EC differentiation [38]. These candidate path-
ways conceivably contribute to the mechanisms by which
the combination of Ang II and VEGF-A drives MSC dif-
ferentiation into ECs. By immunofluorescence, we ob-
served that only a fraction of naïve MSCs express AT1R
and AT2R. This suggests that AT2R-dependent induction
of EC differentiation may be associated with secretion of
mediators from AT2R-expressing cells. Ultimately, such
mediators could have paracrine effects that lead to large-
scale differentiation of MSCs into ECs.
Further investigation is needed to determine whether
or not EC-like cells derived and differentiated from MSCs
are functional in all aspects of EC biology, includingleukocyte/platelet adhesion and the production of vaso-
active substances. With regard to angiogenesis, studies
have shown that both Ang II and VEGF-A promote capil-
lary tube formation, a distinctly EC trait [37,38]. Like-
wise, a pro-angiogenic role for AT2R signaling has been
demonstrated using AT2R-KO mice or mice treated
with AT2R antagonist. Results from the current study also
support a pro-angiogenic role for AT2R [39].
Conclusions
In summary (Figure 8), Ang II-dependent signaling me-
diated by AT2R plays a critical role in the differenti-
ation of BM-MSCs into ECs. Results from this study
highlight the importance of investigating AT1R-specific
effects versus AT2R-specific effects on EC function and
Figure 8 Summary of synergistic effect of angiotensin II on VEGF-A-mediated differentiation of BM-MSCs into endothelial cells. Ang II,
angiotensin II; ATR, angiotensin receptor; BM, MSC, bone-marrow-derived mesenchymal stem cells; PECAM-1, platelet endothelial cell adhesion
molecule-1; VE-cadherin, vascular endothelial cadherin; VEGF, vascular endothelial growth factor; vWF, von Willebrand factor.
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is of clinical importance, given the prevalence of the
use of angiotensin-converting enzyme inhibitors and
angiotensin receptor blockers in the treatment of pa-
tients with vascular disease. Connecting EC differenti-
ation to AT2R signaling could have immediate clinical
and translational application.
Drug-based therapies for cardiovascular diseases that
impair AT2R function may have an unintended effect on
vascular re-endothelialization. For instance, drugs that
prevent formation of Ang II, including angiotensin-
converting enzyme inhibitors [40,41], could have negative
consequences on MSC differentiation into ECs, since Ang
II is an endogenous agonist of AT2R. It is feasible that
AT2R-specific agonists could be beneficial as a supple-
mentary treatment in these cases. Moreover, a better un-
derstanding of AT2R and VEGF-A mechanisms in EC
differentiation could be instrumental in the development
of cell-based therapies towards the re-endothelialization
necessitated by interventional procedures.Abbreviations
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